Emergent Product Development UK Limited

Merial Limited

Microscience Limited

Other

Imperial College Innovations Limited

Vmax Ltd.

Jacqueline Elizabeth Shea

David William Holden

Robert Graham Feldman

Gordon Dougan

Michael Hensel

Joseph David Santangelo

François-Xavier Le Gros

Sylvain Gabriel Goutebroze

Zoe Hindle

Helen Rachel Crooke

Enda Elizabeth Clarke

Paul Howard Everest

Francois Xavier Le Gros

Liqing Zhou

Eva Medina

Sylvain Gabriel Coutebroze

Helen Rachel Veterinary Lab Agency Crooke

François-Xavier Legros

Christoph Hueck

David William Department Of Infectious Diseases Holden

Disclosed and claimed are a mutant of a gram negative bacterium, wherein said bacterium has at least one mutation in a nucleotide sequence which codes for a polypeptide having an identity which is equal or more than 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% with an amino acid sequence coded by a nucleotide sequence selected from the group consisting of nucleotide sequences identified SEQ ID NO: 2, 6, 9, 12, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 75, 78, 81, 84, 87, 90, 93; said mutation resulting in attenuated virulence of the bacterium. Immunogenic compositions and vaccines containing such a mutant are also disclosed and claimed.

Attenuated gram negative bacteria

The present invention relates to vaccines, in particular, to an attenuated gram-negative cell comprising the SPI2 gene locus, wherein at least one gene of the SPI2 locus is inactivated, wherein said inactivation results in an attenuation/reduction of virulence compared to the wild type of said cell, and to a carrier for the presentation of an antigen to a host, which carrier is said attenuated gram-negative cell, wherein said cell comprises at least one heterologous nucleic acid molecule comprising a nucleic acid sequence coding for said antigen, wherein said cell is capable of expressing said nucleic acid molecule or capable of causing the expression of said nucleic acid molecule in a target cell.

Attenuated salmonella SP12 mutants as antigen carriers

The present invention pertains to amicroorganism having an attenuating mutation which disrupts the expression of a gene located within the Spi2 pathogenicity island, and an auxotrophic mutation. The microorganism therefore has a double mutation which helps prevent reactivity of the microorganism while maintaining the effectiveness of the microorganism to elicit an immune response. The present invention also pertains to vaccine compositions and methods for treating and preventing ainfection in a patient.

Attenuated microorganisms for the treatment of infection

[object Object]

A series of genes fromare shown to encode products which are implicated in virulence. The identification of these genes therefore allows attenuated microorganisms to be produced. Furthermore, the genes or their encoded products can be used in the manufacture of vaccines for therapeutic application.

Virulence genes, proteins, and their use

The present invention relates to vaccines, in particular, to an attenuated gram-negative cell comprising the SP12 gene locus, wherein at least one gene of the SP12 locus is inactivated, wherein the inactivation results in an attenuation/reduction of virulence compared to the wild type of said cell, and to a carrier for the presentation of an antigen to a host, which carrier is the attenuated gram-negative cell, wherein the cell comprises at least one heterologous nucleic acid molecule comprising a nucleic acid sequence coding for the antigen, wherein the cell is capable of expressing the nucleic acid molecule or capable of causing the expression of the nucleic acid molecule in a target cell.

The present invention is based on the identification of a series of virulence genes inK1, the products of which may be implicated in the pathogenicity of the organisms. The identification of the genes allows them, or their expressed products, to be used in a number of ways to treat infection.

Virulence genes and proteins, and their use

The present invention pertains to a Salmonella microorganism having an attenuating mutation which disrupts the expression of a gene located within the Spi2 pathogenicity island, and an auxotrophic mutation. The microorganism therefore has a double mutation which helps prevent reactivity of the microorganism while maintaining the effectiveness of the microorganism to elicit an immune response. The present invention also pertains to vaccine compositions and methods for treating and preventing a Salmonella infection in a patient.

Identification of genes

Growing community of inventors

High Wycombe, United Kingdom

Jacqueline Elizabeth Shea